Fundraising FoxBVCF — 2015 Investments
1 investments dated 2015 · listed companies and verified rows first · show all
DiaCartadiacarta.comSeries A · Jan 2015 · $8M
DiaCarta is a precision diagnostics company developing molecular technologies (XNA and isobDNA) to detect genetic mutations for cancer patient management—covering early detection, diagnosis, therapy selection, and monitoring—as well as infectious disease testing.
BiotechDigital HealthMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.